학술논문

Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States Before the Delta- and Omicron-Associated Surges: A Retrospective Cohort Study of Repeat Blood Donors
Document Type
article
Source
The Journal of Infectious Diseases. 226(9)
Subject
Emerging Infectious Diseases
Immunization
Infectious Diseases
Clinical Research
Prevention
Vaccine Related
3.4 Vaccines
Prevention of disease and conditions
and promotion of well-being
Infection
Good Health and Well Being
Humans
United States
COVID-19 Vaccines
COVID-19
Retrospective Studies
Blood Donors
Vaccine Efficacy
Cohort Studies
blood donors
SARS-CoV-2
vaccine effectiveness
vaccines
Biological Sciences
Medical and Health Sciences
Microbiology
Language
Abstract
BackgroundTo inform public health policy, it is critical to monitor coronavirus disease 2019 vaccine effectiveness (VE), including against acquiring infection.MethodsWe estimated VE using self-reported vaccination in a retrospective cohort of repeat blood donors who donated during the first half of 2021, and we demonstrated a viable approach for monitoring VE via serological surveillance.ResultsUsing Poisson regression, we estimated an overall VE of 88.8% (95% confidence interval, 86.2-91.1), adjusted for demographic covariates and variable baseline risk.ConclusionsThe time since first reporting vaccination, age, race and/or ethnicity, region, and calendar time were statistically significant predictors of incident infection.